pro version 4 3 1 software (Molecular Devices LLC)
Molecular Devices LLC is a verified supplier 
Molecular Devices LLC manufactures this product 
96
Structured Review
Molecular Devices LLC
pro version 4 3 1 software
Pro Version 4 3 1 Software, supplied by Molecular Devices LLC, used in various techniques. Bioz Stars score: 96/100, based on 3068 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+software+version+4+3+1/SoftMax+Pro+Software/pmc07352940-217-16-20
Average 96 stars, based on 3068 article reviews
Pro Version 4 3 1 Software, supplied by Molecular Devices LLC, used in various techniques. Bioz Stars score: 96/100, based on 3068 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+software+version+4+3+1/SoftMax+Pro+Software/pmc07352940-217-16-20
Average 96 stars, based on 3068 article reviews
pro version 4 3 1 software - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Inhibition:Article Title: Caveolae optimize tissue factor–Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor Article Snippet: .. Cells were harvested and mixed with fVIIa (0.02 nM for the TFPI inhibition assay in Figure 1E and 0.01 nM in all other Figures) and fXa chromogenic substrate (500 μM). fX (Factor X) (20 nM) (all final concentrations) was added and substrate cleavage was monitored at 405 nm for 1 h. The maximal rate of substrate cleavage, calculated by SoftMAX Software:Article Title: Caveolae optimize tissue factor–Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor Article Snippet: .. Cells were harvested and mixed with fVIIa (0.02 nM for the TFPI inhibition assay in Figure 1E and 0.01 nM in all other Figures) and fXa chromogenic substrate (500 μM). fX (Factor X) (20 nM) (all final concentrations) was added and substrate cleavage was monitored at 405 nm for 1 h. The maximal rate of substrate cleavage, calculated by SoftMAX Article Title: Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Article Snippet: Background and objective: Tumor necrosis factor (TNF) antagonists, including etanercept (a soluble TNF receptor) and infliximab (an anti-TNF monoclonal antibody) are used in the treatment of patients with rheumatoid arthritis (RA).. The purpose of this study was to evaluate the effectiveness and safety of 50 mg etanercept weekly in subjects with RA who have failed infliximab therapy.. Methods: This phase 4, multicenter, open-label, single-arm, 16-week observational study enrolled subjects who had experienced primary (failure to achieve an initial response) or secondary (failure to maintain an initial response) infliximab failures. Article Title: Caveolae Optimize Tissue Factor-Factor VIIa Inhibitory Activity of Cell Surface Associated Tissue Factor Pathway Inhibitor Article Snippet: .. The maximal rate of substrate cleavage, calculated by SoftMAX Generated:Article Title: Caveolae optimize tissue factor–Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor Article Snippet: .. Cells were harvested and mixed with fVIIa (0.02 nM for the TFPI inhibition assay in Figure 1E and 0.01 nM in all other Figures) and fXa chromogenic substrate (500 μM). fX (Factor X) (20 nM) (all final concentrations) was added and substrate cleavage was monitored at 405 nm for 1 h. The maximal rate of substrate cleavage, calculated by SoftMAX Article Title: Caveolae Optimize Tissue Factor-Factor VIIa Inhibitory Activity of Cell Surface Associated Tissue Factor Pathway Inhibitor Article Snippet: .. The maximal rate of substrate cleavage, calculated by SoftMAX |